Some of Dr. Kostenuik's publications in the immunology field:

Dr. Kostenuik's background in immunology relates primarily to osteoimmunology, a sub-discipline

that recognizes and studies the numerous interactions between immune cells and bone cells. The

RANK-RANKL pathway, which has major influences on osteoclasts, is also expressed  by immune cells,

which triggered extensive research on effects of RANKL and RANKL inhibitors on immune function.

Immunology

Genetic models in applied physiology: Effect of spaceflight on immunity in the C57BL/6 mouse, Part I:  Immune population distribution. Pecaut MJ, Nelson GA, Peters LL, Kostenuik PJ, et al. J Applied Physiol 94: 2085-2094, 2003. PMID: 12514166

 Genetic models in applied physiology: Effect of spaceflight on immunity in the C57BL/6 mouse, Part II: Activation, cytokines, erythrocytes, and platelets. Gridley DS, Nelson GA, Peters LL, et al. J Applied Physiol 94: 2095-2103, 2003. PMID: 12506046

 CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Byrne FB, Morony S, Warmington K, et al. Gut 54: 78-86, 2005. PMID: 15591508

Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. Stolina M, Dwyer D, Zack D, and Kostenuik PJ. J Immunol 179: 7497-7505, 2007. PMID: 18025194

 The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. Stolina M, Bolon B, Middleton S, et al. Biomarkers 13: 692-712, 2008.

PMID: 19096963

The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. Stolina M, Bolon B, Middleton S, Dwyer D, et al. J Clin Immunol 29: 158-174, 2009. PMID: 18726678

RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNF-alpha or anti-IL-1 therapies. Stolina M, Schett G, Dwyer D, et al. Arthr Res Ther 11: R187 (doi:10.1186/ar2879), 2009.

PMID: 20003323

Pro-resorptive cytokines and hormones increase OPGL mRNA expression in primary human osteoblast cultures, while having variable effects on OPG mRNA.  Shalhoub V, Scully S, Rattan A, Kelly M, Grisanti M, Kostenuik PJ, Boyle W, Dunstan C and Lacey DL. J Bone Miner Res 15: S209, 2000 (Abstract)

RANKL inhibition with osteoprotegerin (OPG) prevents bone loss but does not affect immune status in arthritic Rats. M. Stolina, S. Adamu, D. Dwyer, F. Asuncion, M. Ominsky, G. Schett, U. Feige, P. Kostenuik, D. J. Zack. J Bone Miner Res 20 (Suppl. 1): S257, 2005 (Abstract).

Rats and mice overexpressing soluble OPG have high bone mass but no alteration in immunological parameters or lymphocyte function. Stolina M, Dywer D, Morony S, Corbin T, McCabe J, Zack D, Kostenuik PJ. Arthritis and Rheumatism 20 (Suppl) S708, 2005 (Abstract).

Continuous RANKL inhibition in OPG transgenic mice is not associated with changes in innate or humoral immune responses. Stolina M, Dwyer D, and Kostenuik PJ. Annals Rheum Dis 65 (Suppl. 2): 75, 2006 (Abstract)

Long-term denosumab treatment of non-human primates had no observed effects on leukocyte subsets or T-cell-dependent immune responses. Stolina M, Ominsky MS, Schroeder J, Atkinson JE, Smith SY, LeSauteur L, Corneu S, Kostenuik PJ. Aegean Conferences Series, Vol. 35: 98 2008 (Abstract)